| Product Code: ETC8141364 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Malaysia mRNA Vaccines and RNAi Therapeutics Market Overview |
3.1 Malaysia Country Macro Economic Indicators |
3.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F |
3.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market - Industry Life Cycle |
3.4 Malaysia mRNA Vaccines and RNAi Therapeutics Market - Porter's Five Forces |
3.5 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Administration, 2021 & 2031F |
3.7 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By End user, 2021 & 2031F |
4 Malaysia mRNA Vaccines and RNAi Therapeutics Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic diseases in Malaysia |
4.2.2 Growing investments in healthcare infrastructure and research and development |
4.2.3 Government support and initiatives to promote innovative therapies |
4.3 Market Restraints |
4.3.1 High cost of mRNA vaccines and RNAi therapeutics |
4.3.2 Limited awareness and acceptance of mRNA vaccines and RNAi therapeutics among healthcare professionals and patients |
4.3.3 Regulatory challenges and approval processes for new therapies |
5 Malaysia mRNA Vaccines and RNAi Therapeutics Market Trends |
6 Malaysia mRNA Vaccines and RNAi Therapeutics Market, By Types |
6.1 Malaysia mRNA Vaccines and RNAi Therapeutics Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hereditary transthyretin-mediated amyloidosis genetic, 2021- 2031F |
6.1.4 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Acute hepatic porphyria, 2021- 2031F |
6.1.5 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Primary hyperoxaluria type 1, 2021- 2031F |
6.1.6 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Atherosclerotic cardiovascular disease, 2021- 2031F |
6.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market, By Administration |
6.2.1 Overview and Analysis |
6.2.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By IV infusion, 2021- 2031F |
6.2.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market, By End user |
6.3.1 Overview and Analysis |
6.3.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Research Institutes, 2021- 2031F |
6.3.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hospitals and Clinics, 2021- 2031F |
7 Malaysia mRNA Vaccines and RNAi Therapeutics Market Import-Export Trade Statistics |
7.1 Malaysia mRNA Vaccines and RNAi Therapeutics Market Export to Major Countries |
7.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Imports from Major Countries |
8 Malaysia mRNA Vaccines and RNAi Therapeutics Market Key Performance Indicators |
8.1 Number of clinical trials for mRNA vaccines and RNAi therapeutics in Malaysia |
8.2 Research and development expenditure in the biopharmaceutical sector |
8.3 Number of partnerships and collaborations between local and international pharmaceutical companies in the mRNA vaccines and RNAi therapeutics space |
9 Malaysia mRNA Vaccines and RNAi Therapeutics Market - Opportunity Assessment |
9.1 Malaysia mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Administration, 2021 & 2031F |
9.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By End user, 2021 & 2031F |
10 Malaysia mRNA Vaccines and RNAi Therapeutics Market - Competitive Landscape |
10.1 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenue Share, By Companies, 2024 |
10.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here